Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study

Zhang, Wei; Zhao, Guiyang; Fan, Wei; Zhao, Taihong

doi:10.1186/s12886-021-01920-8

Cited by 8 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conbercept can block the activation of VEGF and SDF-1 receptors by binding to the receptors of VEGF and SDF-1, prevent the expression of VEGF and SDF-1 in cells, and indirectly reduce the expression of IL-6 [ 27 ]. Eventually, it reduces the expression of VEGF, SDF-1, and IL-6, inhibits endothelial cell proliferation and angiogenesis, and prevents increased foveal thickness and increased macular partial size in patients [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Intravitreal Injection of Triamcinolone Acetonide and Conbercept for Intraocular Lens after Cataract Surgery

Tang¹,

Wang

Luo³

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To investigate the effect of intravitreal injection of triamcinolone acetonide and conbercept on the efficacy and safety of diabetic macular edema (DME) after cataract intraocular lens (IOL) surgery. Methods. A total of 350 patients with cataract complicated with diabetic macular edema in our hospital from January 2017 to July 2021 were randomly divided into conbercept group and triamcinolone acetonide group. Patients in the conbercept group were given intravitreal injection of conbercept during IOL surgery, and patients in the triamcinolone acetonide group were given injection of triamcinolone acetonide during surgery. Results. Three months after treatment, the best-corrected visual acuity of the two groups was significantly higher than before, the corrected visual acuity of the conbercept group was more significant than the triamcinolone acetonide group, and the intraocular pressure of the triamcinolone acetonide group was higher than the conbercept group. The foveal thickness and macular volume were significantly reduced in both groups, and was reduced more in the conbercept group than in the triamcinolone acetonide group. The contents of VEGF, SDF-1, and IL-6 in both groups were significantly decreased, and the decrease was more significant in the conbercept group than in the triamcinolone acetonide group. The patients with elevated intraocular pressure, headache and vomiting, orbital swelling pain, eye swelling pain, and eye pain in the triamcinolone acetonide group were significantly higher than those in the conbercept group ( P < 0.05 ). Conclusions. Conbercept and triamcinolone acetonide has a good therapeutic effect on DME in pseudophakic eyes after cataract IOL surgery, which can reduce the degree of macular edema and improve the visual function. However, the therapeutic effect of injection therapy with conbercept is safe, the prognosis is better, and the complication rate is low.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Intravitreal Injection of Triamcinolone Acetonide and Conbercept for Intraocular Lens after Cataract Surgery

Tang¹,

Wang

Luo³

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Zhang et al reported that there was no significant difference in change of BCVA and CMT between IVC before and after PRP group. For IVC after PRP therapy, the result of subgroup analysis in our study showed that eyes received PRP combined with earlier (≤ 1 month) or later (> 1 month) anti-VEGF therapy were also no significant difference for outcomes [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Panretinal photocoagulation plus intravitreal conbercept for diabetic retinopathy in real world: a retrospective study

Wang,

Yao,

et al. 2023

BMC Ophthalmol

View full text Add to dashboard Cite

Background To evaluate outcomes of panretinal photocoagulation (PRP) plus intravitreal conbercept (IVC) for diabetic retinopathy (DR) in real world and explore risk factors for patients with poor reactivity and presence of vision-threatening complications after combination treatment. Methods Retrospective review of DR patients received PRP plus IVC over 6 months. The main outcome was improvement ≥ 2 steps in ETDRS diabetic retinopathy severity scale (DRSS) levels. Different strategies for eyes receiving IVC within or over 1 month after PRP were analyzed. For patients with DRSS improvement < 2 steps and presence of vision-threatening adverse events, a binary logistic regression method was used to select risk factors. Results Sixty one eyes were involved in this study. After treated with combination therapy with a median number of 3 injections, 44% of eyes improved ≥ 2 steps in DRSS levels. A total of 14 eyes (23%) occurred vision-threatening adverse events. No significant difference was found in eyes receiving conbercept within or over 1 month after PRP. Duration of diabetes (OR 0.849, 95%CI 0.734–0.982, P = 0.027), GFR (OR 0.961, 95%CI 0.933–0.990, P = 0.010) and baseline DRSS levels (OR 3.290, 95%CI 1.483–7.295, P = 0.003) were independent risk factors for DRSS improvement < 2 steps after treatment. Occurrence of vision-threatening complications was only related to high DRSS levels (OR 3.668, 95%CI 1.710–7.868, P = 0.001). Conclusions The combination therapy was effective for most patients with DR in real world. Eyes received PRP combined with earlier or later conbercept was demonstrated no significant difference for outcomes. For patients with poor renal function, high DRSS levels or occurred DR at the early stage of diabetes, follow-up should be strengthened.

show abstract

“…Analysis of the data before and after the four treatment periods revealed that laser photocoagulation combined with conbercept injection had a better treatment effect on DME, which can effectively improve the visual quality of patients and inhibit retinal thickening[ 21 ]. Retinal laser photocoagulation reduces macular edema in the following two ways: One is by blocking the capillary network through the thermal effect of the laser, which decreases the permeability of the retina and reduces the infiltration rate; and other is in the retinal epithelium that damages the photoreceptor cells in the retina and decreases their VEGF expression, which decreases angiogenesis in the retina and improves its hypoxic state.…”

Section: Discussionmentioning

confidence: 99%

Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines

Zhan¹,

Zhou²,

Zhang³

et al. 2023

World J Diabetes

View full text Add to dashboard Cite

The incidence of type 2 diabetes mellitus is growing in epidemic proportions and has become one of the most critical public health concerns. Cardiovascular complications associated with diabetes are the leading cause of morbidity and mortality. The cardiovascular diseases that accompany diabetes include angina, myocardial infarction, stroke, peripheral artery disease, and congestive heart failure. Among the various risk factors generated secondary to hyperglycemic situations, advanced glycation end products (AGEs) are one of the important targets for future diagnosis and prevention of diabetes. In the last decade, AGEs have drawn a lot of attention due to their involvement in diabetic patho-physiology. AGEs can be derived exogenously and endogenously through various pathways. These are a nonhomogeneous, chemically diverse group of compounds formed nonenzymatically by condensation between carbonyl groups of reducing sugars and free amino groups of protein, lipids, and nucleic acid. AGEs mediate their pathological effects at the cellular and extracellular levels by multiple pathways. At the cellular level, they activate signaling cascades via the receptor for AGEs and initiate a complex series of intracellular signaling resulting in reactive oxygen species generation, inflammation, cellular proliferation, and fibrosis that may possibly exacerbate the damaging effects on cardiac functions in diabetics. AGEs also cause covalent modifications and cross-linking of serum and extracellular matrix proteins; altering their structure, stability, and functions. Early diagnosis of diabetes may prevent its progression to complications and decrease its associated comorbidities. In the present review, we recapitulate the role of AGEs as a crucial mediator of hyperglycemia-mediated detrimental effects in diabetes-associated complications. Furthermore, this review presents an overview of future perspectives for new therapeutic interventions to ameliorate cardiovascular complications in diabetes.

show abstract

Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study

Cited by 8 publications

References 27 publications

Efficacy and Safety of Intravitreal Injection of Triamcinolone Acetonide and Conbercept for Intraocular Lens after Cataract Surgery

Efficacy and Safety of Intravitreal Injection of Triamcinolone Acetonide and Conbercept for Intraocular Lens after Cataract Surgery

Panretinal photocoagulation plus intravitreal conbercept for diabetic retinopathy in real world: a retrospective study

Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines

Contact Info

Product

Resources

About